STOCK TITAN

ThermoGenesis Holdings, Inc. - $THMO STOCK NEWS

Welcome to our dedicated page for ThermoGenesis Holdings news (Ticker: $THMO), a resource for investors and traders seeking the latest updates and insights on ThermoGenesis Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ThermoGenesis Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ThermoGenesis Holdings's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.68%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.54%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.2%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
98.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-52.17%
Tags
ThermoGenesis Holdings, Inc.

Nasdaq:THMO

THMO Rankings

THMO Stock Data

5.37M
1.38M
4.11%
2.27%
1.76%
Other Industrial Machinery Manufacturing
Manufacturing
Link
United States of America
RANCHO CORDOVA

About THMO

thermogenesis holdings, inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (car)-t and other cell-based therapies. it markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed car-txpress platform, which streamlines the manufacturing process for the emerging car-t immunotherapy market. the company operates through two segments, device and clinical development. it manufactures and markets products for clinical bio-banking applications, including axp automated cell separation system, an automated cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood; and bioarchive automated cryopreservation system, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical appli